Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 27;3(1):86-90.
doi: 10.1002/epi4.12086. eCollection 2018 Mar.

Are doses of lamotrigine or levetiracetam adjusted during pregnancy?

Noni Richards  1 , David Reith  2 , Michael Stitely  2 , Alesha Smith  1   3
Affiliations

Are doses of lamotrigine or levetiracetam adjusted during pregnancy?

Noni Richards et al. Epilepsia Open. .

Abstract

Subtherapeutic levels of lamotrigine and levetiracetam are more likely to occur during pregnancy owing to the effect of pregnancy on their pharmacokinetics. This can lead to suboptimal control of epilepsy, and guidelines recommend proactive dose adjustment in the second and third trimesters alongside therapeutic drug monitoring (TDM). This retrospective cohort study using administrative databases aimed to investigate whether prescribers adjust the dose of lamotrigine or levetiracetam during and after pregnancy and whether TDM is used to manage dose adjustment. In 460 individual pregnancies, 232 women (61.4%) had their lamotrigine dose increased in the second and third trimesters and 44 women (53.7%) had their levetiracetam dose increased. Only 57 women (12.4%) had any TDM. The dose was not always decreased postpartum, and 157 women (56.9% of those who had escalated doses during pregnancy) had dose reduced following birth. Between 2012 and 2015, 29 women had an epilepsy-coded hospital discharge during pregnancy and were more likely to have had their dose of lamotrigine or levetiracetam increased. Overall, doses of lamotrigine and levetiracetam were not increased during pregnancy in 40% of the study population, dose changes were not often guided by TDM, and doses were not always reduced postpartum.

Keywords: Epilepsy; Lamotrigine; Levetiracetam; New Zealand; Pregnancy; Therapeutic drug monitoring.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage change in dose from baseline.
See this image and copyright information in PMC

References

    1. Kapoor D, Wallace S. Trends in maternal deaths from epilepsy in the United Kingdom: a 30‐year retrospective review. Obstet Med 2014;7:160–164. - PMC - PubMed
    1. Kloster R, Engelskjon T. Sudden unexpected death in epilepsy (SUDEP): a clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry 1999;67:439–444. - PMC - PubMed
    1. PMMRC . Ninth Annual Report of the Perinatal and Maternal Mortality Review Committee: reporting mortality 2013. Wellington: Health Quality & Safety Commission; 2015.
    1. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013;54:405–414. - PubMed
    1. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008;70:2130–2136. - PMC - PubMed

LinkOut - more resources